The Possible Role of Sirtuins and MicroRNAs in Hepatocellular Carcinoma Therapy

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2020 Nov 9

PMID 33164623

Citations 7

Authors

Hedyieh Karbasforooshan

A Wallace Hayes

Nooshin Mohammadzadeh

Mohammad Reza Zirak

Gholamreza Karimi

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Sirtuins are NAD+-dependent histone deacetylases that regulate many cellular processes such as proliferation, apoptosis, and metabolism. SIRT (silent information regulator)-1, 5, 6 and 7, members of the mammalian Sirtuin family of proteins (SIRT1-SIRT7), are involved in carcinogenesis, prognosis, metastasis, and chemical resistant of HCC. These proteins act through the deacetylation of tumor suppressor or oncogenic factors. MicroRNAs (miRNAs) are a group of small non-coding RNAs that down regulate gene expression by targeting the 3'-untranslated region of miRNAs. MiRNAs can function as tumor suppressors or as oncogenes and are involved in progression, differentiation, apoptosis and drug resistance of tumor cells. The focus of this review is to delineate the relationship between some microRNAs and their target, Sirtuins, and to present an overview of their function in HCC as currently understood.

Citing Articles

FXR, MRP-1 and SLC7A5: New Targets for the Treatment of Hepatocellular Carcinoma.

Zhang X, Luo M, Qin S, Fu W, Zhang M Technol Cancer Res Treat. 2024; 23:15330338241276889.

PMID: 39194338 PMC: 11363239. DOI: 10.1177/15330338241276889.

The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes.

Farsi N, Naghipour B, Shahabi P, Safaralizadeh R, Hajiasgharzadeh K, Dastmalchi N Clin Exp Hepatol. 2024; 9(4):307-319.

PMID: 38774201 PMC: 11103798. DOI: 10.5114/ceh.2023.131669.

Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response.

Ji Y, Li C, Wan S, Zhang K, Liu Y, Shi S Funct Integr Genomics. 2024; 24(2):60.

PMID: 38499806 DOI: 10.1007/s10142-024-01338-7.

The modulation of sirtuins by natural compounds in the management of cisplatin-induced nephrotoxicity.

Zare S, Karbasforooshan H, Wallace Hayes A, Karimi G Naunyn Schmiedebergs Arch Pharmacol. 2022; 396(4):693-703.

PMID: 36454257 DOI: 10.1007/s00210-022-02353-w.

Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.

Fang W, Song L, Li Z, Meng P, Zuo S, Liu S Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(10):1303-1314.

PMID: 36411681 PMC: 10930361. DOI: 10.11817/j.issn.1672-7347.2022.210521.

References

Qin H, Ruan Z . The role of monoacylglycerol lipase (MAGL) in the cancer progress. Cell Biochem Biophys. 2014; 70(1):33-6. DOI: 10.1007/s12013-014-9899-2. View

Shukla G, Singh J, Barik S . MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2012; 3(3):83-92. PMC: 3315687. View

Zhang H, Feng Z, Huang R, Xia Z, Xiang G, Zhang J . MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol. 2014; 45(5):2143-52. DOI: 10.3892/ijo.2014.2596. View

Yang F, Gong J, Wang G, Chen P, Yang L, Wang Z . Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway. Oncotarget. 2016; 7(46):75165-75175. PMC: 5342731. DOI: 10.18632/oncotarget.12614. View

Karbasforooshan H, Roohbakhsh A, Karimi G . SIRT1 and microRNAs: The role in breast, lung and prostate cancers. Exp Cell Res. 2018; 367(1):1-6. DOI: 10.1016/j.yexcr.2018.03.023. View

Cassim S, Raymond V, Dehbidi-Assadzadeh L, Lapierre P, Bilodeau M . Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle. 2018; 17(7):903-916. PMC: 6056217. DOI: 10.1080/15384101.2018.1460023. View

Guo L, Bai H, Zou D, Hong T, Liu J, Huang J . The role of microRNA-133b and its target gene FSCN1 in gastric cancer. J Exp Clin Cancer Res. 2014; 33:99. PMC: 4272783. DOI: 10.1186/s13046-014-0099-0. View

Wang W, Zhao L, Tan Y, Ren H, Qi Z . MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 2012; 33(5):1113-20. PMC: 3334515. DOI: 10.1093/carcin/bgs113. View

Rastogi N, Mishra D . Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div. 2012; 7(1):26. PMC: 3584802. DOI: 10.1186/1747-1028-7-26. View

10.

Xiong H, Ni Z, Jiang S, Li X, He J, Gong W . LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017; 36(25):3528-3540. DOI: 10.1038/onc.2016.521. View

11.

Lin C, Gong H, Tseng H, Wang W, Wu J . miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008; 375(3):315-20. DOI: 10.1016/j.bbrc.2008.07.154. View

12.

Huang X, Jian W, Wu Z, Zhao J, Wang H, Li W . Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation. Oncotarget. 2014; 5(14):5570-80. PMC: 4170598. DOI: 10.18632/oncotarget.2141. View

13.

Zhao L, Wang W . miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7. Int J Clin Exp Med. 2016; 8(10):18469-75. PMC: 4694354. View

14.

Kim J, Noh J, Jung K, Eun J, Bae H, Kim M . Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 2012; 57(3):1055-67. DOI: 10.1002/hep.26101. View

15.

Pant K, Yadav A, Gupta P, Islam R, Saraya A, Venugopal S . Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells. Redox Biol. 2017; 12:340-349. PMC: 5350572. DOI: 10.1016/j.redox.2017.03.006. View

16.

Ulitsky I, Bartel D . lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154(1):26-46. PMC: 3924787. DOI: 10.1016/j.cell.2013.06.020. View

17.

Liu X, Yang L, Tu J, Cai W, Zhang M, Shou Z . microRNA-526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma. Oncotarget. 2017; 8(50):87737-87749. PMC: 5675668. DOI: 10.18632/oncotarget.21209. View

18.

Cheng L, Zhu Y, Han H, Zhang Q, Cui K, Shen H . MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. Cell Death Dis. 2017; 8(7):e2916. PMC: 5550856. DOI: 10.1038/cddis.2017.309. View

19.

Xiong Y, Fang J, Yun J, Yang J, Zhang Y, Jia W . Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2009; 51(3):836-45. DOI: 10.1002/hep.23380. View

20.

Tian Z, Jiang H, Liu Y, Huang Y, Xiong X, Wu H . MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res. 2016; 343(2):135-147. DOI: 10.1016/j.yexcr.2016.03.027. View